Non-Hodgkin lymphoma is an aggressive cancer of lymph against which the scientists are striving hard to find potent drugs. In this regard, Seattle Genetics’ cancer drug Adcetris has won FDA approval for the treatment of a rapid-growing type of non-Hodgkin lymphoma. FDA approved the drug when it depicted outstanding results in patients as compared to the standard treatments.
Adcetris is the first ever drug approved from FDA in a short period of two weeks for treating the newly diagnosed peripheral T-cell lymphoma (PTCL). PTCL develops from white blood cells called T-cells and is an aggressive and rare type of non-Hodgkin lymphoma.
The CEO of Seattle Genetics, Clay Siegall recognized the services of FDA’s new Real-Time Oncology Review program in approving the drug in less than two weeks after submission. FDA reviews the drug data before receiving an official application under the pilot program.
Chemotherapy produces numerous side effects and compromised survival rates. The combined therapy of Adcetris and chemotherapy produces a synergistic effect on the survival rates and other outcomes, as compared to the chemotherapy alone. Adcetris is also a first-line treatment for classical Hodgkin’s lymphoma and this is the sixth FDA-approved use for Adcetris in the treatment of non-Hodgkin’s lymphoma.
Seattle Genetics is generating huge revenue through the sales of Adcetris in North America, developed in collaboration with Takeda in Japan. Adcetris sales rose to about 54% in the first nine months of 2018 in the U.S. and Canada, as compared with the same period in 2017. Genetics has increased the stock of Seattle Genetics to more than 6%.